OliPass Terminates Joint Research and Development Agreement for Muscle Rare Disease Treatment
[Asia Economy Reporter Geum Bo-ryeong] Olipass announced on the 4th that it received a notice of termination of the strategic joint research and development contract for a muscle rare disease treatment from Company A (a US-based rare disease new drug development biotech), the counterparty of the strategic joint research contract.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- 59% of Americans Say "U.S. Prime Has Already Passed"... 44% Pessimistic About Next 50 Years
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The termination effective date is August 1. The sales amount related to the contract is 367.56 million KRW, which accounts for more than 10% of recent sales.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
